T1	p 124 141	type 1 diabetes .
T2	p 562 628	24 patients , 8-18 years old , with newly diagnosed T1D . Subjects
T3	p 692 724	after initial diagnosis of T1D .
T4	i 6 26	Insulin pump therapy
T5	i 320 340	insulin pump therapy
T6	i 383 390	insulin
T7	i 485 556	MDI therapy with continuous subcutaneous insulin therapy ( pump therapy
T8	i 943 957	glucose sensor
T9	i 1614 1626	insulin pump
T10	o 73 81	glycemic
T11	o 183 218	residual insulin secretory capacity
T12	o 741 760	insulin secretion ,
T13	o 770 816	by mixed-meal-stimulated C-peptide secretion ,
T14	o 896 1050	glycosylated hemoglobin ( HbA1c ) , continuous glucose sensor data , insulin utilization , anthropometric measures , and patient satisfaction with therapy
T15	o 1184 1244	higher mixed-meal tolerance test-stimulated C-peptide values
T16	o 1353 1369	glycemic control
T17	o 1439 1452	normoglycemia
T18	o 1473 1474	)
T19	o 1534 1546	satisfaction
T20	o 1657 1673	glycemic control
T21	o 1685 1696	tolerated ,
T22	o 1725 1745	patient satisfaction
T23	o 1844 1868	residual ?-cell function